Literature DB >> 15384080

Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation.

Débora Romeo Bertola1, Alexandre C Pereira, Paulo S L de Oliveira, Chong A Kim, José Eduardo Krieger.   

Abstract

Noonan syndrome (NS) is an autosomal dominant disorder comprising short stature, facial dysmorphism, short and/or webbed neck, heart defects, and cryptorchidism in males. The gene responsible for the disorder (PTPN11) was recently identified, and explains 30-50% of the cases clinically diagnosed as NS. Cardiofaciocutaneous (CFC) syndrome, a similar but distinct entity, is characterized by relative macrocephaly, characteristic facial appearance, ectodermal abnormalities (sparse and friable hair, sparse eyebrows, hyperkeratotic skin), congenital heart defects, and growth and mental retardation. We describe on a young woman who presents clinical features of NS (short stature, triangular facies, with downslanting palpebral fissures and apparent hypertelorism, webbed neck, pulmonary stenosis, bleeding diathesis, prominent corneal nerves), but with a more prominent ectodermal involvement (sparse and very coarse hair, sparse eyebrows and eyelashes) and developmental delay/mental retardation, which are characteristic of CFC patients. Sequencing of the PTPN11 gene showed a T411M substitution, not previously described in patients with NS. The same mutation was found in her mother and older sister, not initially considered to be affected by NS, but with very subtle clinical findings compatible with this diagnosis. Molecular dynamic studies indicate that this new mutation, similar to other previously described mutations, favors a more active protein conformation. However, the main disruptive effect is not directly in the catalytic domain, suggesting that the location of this mutation could make the protein more susceptible to gene-gene or gene-environment interactions. Atypical cases of NS should be screened for mutations in the PTPN11 gene and in the case of a positive result, first-degree relatives should also be tested for the specific mutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15384080     DOI: 10.1002/ajmg.a.30270

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  11 in total

1.  A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development.

Authors:  Karen W Gripp; Eugenia Bifeld; Deborah L Stabley; Elizabeth Hopkins; Stefanie Meien; Kathy Vinette; Katia Sol-Church; Georg Rosenberger
Journal:  Am J Med Genet A       Date:  2012-07-20       Impact factor: 2.802

2.  Genetic counseling in the adult with congenital heart disease: what is the role?

Authors:  Luke Burchill; Steven Greenway; Candice K Silversides; Seema Mital
Journal:  Curr Cardiol Rep       Date:  2011-08       Impact factor: 2.931

3.  MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.

Authors:  Xue Wu; Jeremy Simpson; Jenny H Hong; Kyoung-Han Kim; Nirusha K Thavarajah; Peter H Backx; Benjamin G Neel; Toshiyuki Araki
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

4.  Identification of key genes and signaling pathways related to Hetian sheep wool density by RNA-seq technology.

Authors:  Ruijun Shi; Shuwei Li; Penggang Liu; Shuhui Zhang; Zhenhui Wu; Tinghui Wu; Shujuan Gong; Yu Wan
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

5.  Clinical manifestations in patients with SOS1 mutations range from Noonan syndrome to CFC syndrome.

Authors:  Yoko Narumi; Yoko Aoki; Tetsuya Niihori; Masahiro Sakurai; Hélène Cavé; Alain Verloes; Kimio Nishio; Hirofumi Ohashi; Kenji Kurosawa; Nobuhiko Okamoto; Hiroshi Kawame; Seiji Mizuno; Tatsuro Kondoh; Marie-Claude Addor; Anne Coeslier-Dieux; Catherine Vincent-Delorme; Koichi Tabayashi; Masashi Aoki; Tomoko Kobayashi; Afag Guliyeva; Shigeo Kure; Yoichi Matsubara
Journal:  J Hum Genet       Date:  2008-07-24       Impact factor: 3.172

6.  Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.

Authors:  Toshiyuki Araki; Gordon Chan; Susan Newbigging; Lily Morikawa; Roderick T Bronson; Benjamin G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-27       Impact factor: 11.205

7.  Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.

Authors:  Marco Tartaglia; Simone Martinelli; Lorenzo Stella; Gianfranco Bocchinfuso; Elisabetta Flex; Viviana Cordeddu; Giuseppe Zampino; Ineke van der Burgt; Antonio Palleschi; Tamara C Petrucci; Mariella Sorcini; Claudia Schoch; Robin Foa; Peter D Emanuel; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2005-12-07       Impact factor: 11.025

8.  Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.

Authors:  Jeevana Praharsha Athota; Meenakshi Bhat; Sheela Nampoothiri; Kalpana Gowrishankar; Sanjeeva Ghanti Narayanachar; Vinuth Puttamallesh; Mohammed Oomer Farooque; Swathi Shetty
Journal:  BMC Med Genet       Date:  2020-03-12       Impact factor: 2.103

9.  ALDH1A2 (RALDH2) genetic variation in human congenital heart disease.

Authors:  Marilene Pavan; Viviane F Ruiz; Fábio A Silva; Tiago J Sobreira; Roberta M Cravo; Michelle Vasconcelos; Lívia P Marques; Sonia M F Mesquita; José E Krieger; Antônio A B Lopes; Paulo S Oliveira; Alexandre C Pereira; José Xavier-Neto
Journal:  BMC Med Genet       Date:  2009-11-03       Impact factor: 2.103

10.  The impact of the genetic background in the Noonan syndrome phenotype induced by K-Ras(V14I).

Authors:  Isabel Hernández-Porras; Beatriz Jiménez-Catalán; Alberto J Schuhmacher; Carmen Guerra
Journal:  Rare Dis       Date:  2015-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.